Big-cap biotech and IBD 50 stock Gilead Sciences put an important brick in its fortress against competition Wednesday when it reported positive trial data for its latest HIV drug. Its stock rose 3% to 108.66 on the news. The drug, called tenofovir alafenamide (TAF), has been nicknamed “Son of Viread” by Wall Street because it’s a new and improved version of Gilead’s (GILD) flagship HIV drug Viread. Since Viread first hit the market in 2001, most
Big-cap biotech and IBD 50 stock Gilead Sciences (GILD) reported good late-stage trial data for its new HIV drug Wednesday. Analysts nicknamed the drug “son of Viread” and expect it to be a blockbuster. The stock was up about 2.2% by afternoon trading on the stock market today. The two trials compared a standard combination of four drugs that are combined in Gilead’s (GILD) most advanced marketed product, Stribild, to one in which one of the
The European Commission (EC) approved Gilead Sciences’ (GILD) drug Zydelig for two blood cancers on Friday, sending Gilead stock up as much as 1.9%, though shares were flat in midday trading in the stock market today. The EC approved the drug for chronic lymphocytic leukemia and follicular lymphoma. For the former, it is to be used in combination with Rituxan (sold jointly by Roche and Biogen Idec (BIIB), and for the latter by itself. The move